Format

Send to

Choose Destination
Sci Signal. 2019 Sep 24;12(600). pii: eaaw8288. doi: 10.1126/scisignal.aaw8288.

A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.

Author information

1
Integrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
2
Mass Spectrometry Core for Proteomics and Metabolomics, Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
3
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
4
Department of Research Biology, Genentech, South San Francisco, CA 94080, USA.
5
Integrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037, USA. estites@salk.edu.

Abstract

Cancer treatment decisions are increasingly guided by which specific genes are mutated within each patient's tumor. For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many colorectal cancer (CRC) patients, with the general exception of those whose tumor includes a KRAS mutation. However, among the various KRAS mutations, that which encodes the G13D mutant protein (KRASG13D) behaves differently; for unknown reasons, KRASG13D CRC patients benefit from the EGFR-blocking antibody cetuximab. Controversy surrounds this observation, because it contradicts the well-established mechanisms of EGFR signaling with regard to RAS mutations. Here, we identified a systems-level, mechanistic explanation for why KRASG13D cancers respond to EGFR inhibition. A computational model of RAS signaling revealed that the biophysical differences between the three most common KRAS mutants were sufficient to generate different sensitivities to EGFR inhibition. Integrated computation with experimentation then revealed a nonintuitive, mutant-specific dependency of wild-type RAS activation by EGFR that is determined by the interaction strength between KRAS and the tumor suppressor neurofibromin (NF1). KRAS mutants that strongly interacted with and competitively inhibited NF1 drove wild-type RAS activation in an EGFR-independent manner, whereas KRASG13D weakly interacted with and could not competitively inhibit NF1 and, thus, KRASG13D cells remained dependent on EGFR for wild-type RAS activity. Overall, our work demonstrates how systems approaches enable mechanism-based inference in genomic medicine and can help identify patients for selective therapeutic strategies.

PMID:
31551296
PMCID:
PMC6864030
[Available on 2020-03-24]
DOI:
10.1126/scisignal.aaw8288

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center